KPV (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. For 10 unit (0.10 mL) or smaller administrations, consider 30- or

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.33 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or below in dry, dark conditions; protect from moisture and light.
• Reconstituted: refrigerate at 2 to 8 °C; use within approximately 30 days.
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Avoid freeze-thaw cycles: do not refreeze reconstituted peptide solutions; prepare aliquots if long-term

storage is needed.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (KPV, 10 mg each):

• 8 weeks: ~3 vials. 12 weeks: ~4 vials. 16 weeks: ~6 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (6 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container immediately after

use.

• Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1 to 2 inches apart.
• Inject slowly; wait a few seconds before withdrawing the needle to prevent solution backflow.
• Document daily dose, injection site, and any observations to maintain consistency and track tolerability.
• If injection-site reactions (redness, mild swelling) occur, apply a cool compress and monitor; persistent

reactions warrant protocol review.

How This Works

KPV is the C-terminal tripeptide sequence (residues 11-13) of a-melanocyte-stimulating hormone (a-MSH), retaining potent anti-inflammatory activity without the hormone's melanotropic effects. Preclinical studies demonstrate KPV reduces pro-inflammatory cytokines (TNF-a, IL-6, IL-1b) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. The peptide's mechanism involves inhibition of nuclear factor kappa B (NF-kB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti-inflammatory effects observed in daily dosing protocols.

Benefits & Side Effects

Observations from preclinical and early-stage research.

• Anti-inflammatory activity: Reduces pro-inflammatory cytokines and modulates immune responses in

models of inflammatory bowel disease and systemic inflammation.

• Multiple routes: Oral and subcutaneous administration show activity, with subcutaneous favored for

systemic delivery and consistent bioavailability.

• Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing

processes through inflammatory modulation.

• Generally well tolerated: Occasional mild injection-site reactions (redness, slight swelling) may occur;

systemic side effects are rarely reported in research protocols.

• No melanotropic effects: Unlike full a-MSH, KPV does not affect melanocyte activity or skin

pigmentation.

Lifestyle Factors

Complementary strategies for best outcomes.

• Anti-inflammatory diet: emphasize whole foods, omega-3 fatty acids, polyphenols; minimize processed

foods and refined sugars.

• Stress management: chronic stress elevates inflammatory markers.
• Physical activity: regular moderate exercise supports healthy inflammatory balance; avoid overtraining.
• Sleep optimization: 7 to 9 hours of quality sleep supports immune regulation and inflammatory

homeostasis.

• Gut health: support microbiome diversity through probiotic-rich foods and adequate fiber intake.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Pawar K et al. KPV as an a-MSH fragment retains anti-inflammatory activity (J Pharm Drug Delivery Research, 2022).
2. Brzoska T et al. a-MSH and related tripeptides: modulation of colitis, inflammation (FASEB Journal, 2003).
3. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation in DSS colitis (Gastroenterology, 2008).